keyword
MENU ▼
Read by QxMD icon Read
search

radiotherapy for carcinoma prostate

keyword
https://www.readbyqxmd.com/read/29723459/-clinicopathological-features-of-primary-seminal-vesicle-adenocarcinoma-a-report-of-4-cases-and-review-of-the-literature
#1
Jia-Ning Guo, Hui Li, Zhan-Dong Hu, En-Li Liang, Ji-Wu Chang
Objective: To investigate the clinicopathological characteristics, diagnosis, and treatment of primary seminal vesicle adenocarcinoma (SVAC). METHODS: We analyzed the clinical data and clinicopathological characteristics of 4 cases of primary SVAC treated in the Department of Urology of the Second Hospital of Tianjin Medical University and reviewed relevant literature. RESULTS: All the 4 patients were treated by open radical resection of the seminal vesicle and prostate and pathologically diagnosed with SVAC...
July 2017: Zhonghua Nan Ke Xue, National Journal of Andrology
https://www.readbyqxmd.com/read/29692814/unusual-presentation-of-prostate-cancer-metastatic-to-the-cricoid-cartilage-and-oral-cavity
#2
Marlene Olvera, Miriam Delgado, Melchor Vázquez, José Zavala, Verónica Macedo, Martha Puentes
In Mexico, prostate cancer is the second leading cause of death in men. Prostate cancer usually presents metastasis to the regional lymph nodes and bone. Hereby, we present an unusual case of metastatic prostate cancer, with affectation to the cricoid cartilage and oral cavity, being the first case to have ever been reported in Mexico. A 68-year-old Mexican man was diagnosed with prostate cancer and cribriform architecture histology with low serum level of prostate-specific antigen, debuting with laryngeal stridor...
2018: Case Reports in Medicine
https://www.readbyqxmd.com/read/29688951/prediction-of-normal-organ-absorbed-doses-for-177lu-lu-psma-617-using-44sc-sc-psma-617-pharmacokinetics-in-patients-with-metastatic-castration-resistant-prostate-carcinoma
#3
Ambreen Khawar, Elisabeth Eppard, Jean Phlippe Sinnes, Frank Roesch, Hojjat Ahmadzadehfar, Stefan Kürpig, Michael Meisenheimer, Florian C Gaertner, Markus Essler, Ralph A Bundschuh
In vivo pharmacokinetic analysis of [Sc]Sc-PSMA-617 was used to determine the normal organ-absorbed doses that may result from therapeutic activity of [Lu]Lu-PSMA-617 and to predict the maximum permissible activity of [Lu]Lu-PSMA-617 for patients with metastatic castration-resistant prostate carcinoma. METHODS: Pharmacokinetics of [Sc]Sc-PSMA-617 was evaluated in 5 patients with metastatic castration-resistant prostate carcinoma using dynamic PET/CT, followed by 3 static PET/CT acquisitions and blood sample collection over 19...
April 23, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29652817/selenium-in-radiation-oncology-15-years-of-experiences-in-germany
#4
REVIEW
Ralph Muecke, Oliver Micke, Lutz Schomburg, Jens Buentzel, Klaus Kisters, Irenaeus A Adamietz
Introduction: Se measurement and supplementation in radiation oncology is a controversial issue. The German Working Group Trace Elements and Electrolytes in Oncology (AKTE) has conducted a number of studies on this issue, which are summarized in this review. Strategies have been tested and developed, aiming to stratify the patients with a potential need for supplemental Se and how best to monitor Se supplementation with respect to health effects and risks. Methods: We analyzed blood and tissue Se-levels of different tumor patients ( n = 512)...
April 13, 2018: Nutrients
https://www.readbyqxmd.com/read/29603326/the-impact-of-intraductal-carcinoma-of-the-prostate-on-the-site-and-timing-of-recurrence-and-cancer-specific-survival
#5
Vincent Q Trinh, Jennifer Sirois, Nazim Benzerdjeb, Babak K Mansoori, Andrée-Anne Grosset, Roula Albadine, Mathieu Latour, Anne-Marie Mes-Masson, Hélène Hovington, Alain Bergeron, Martin Ladouceur, Yves Fradet, Fred Saad, Dominique Trudel
BACKGROUND: To investigate the effect of intraductal carcinoma of the prostate (IDC-P) in radical prostatectomy (RP) specimens in the context of the site of recurrence, time to recurrence, and cancer-specific survival in two academic cohorts of locally, regionally, or distantly recurrent prostate cancer. METHODS: Our cohort included men enrolled into two academic tissue repositories from 1993 to 2011, who were treated with first-line RP who later experienced local recurrence, regional recurrence, or distant metastasis (together termed clinical recurrence, CR)...
March 30, 2018: Prostate
https://www.readbyqxmd.com/read/29594233/uptake-of-prostate-specific-membrane-antigen-psma-in-adenoid-cystic-carcinoma-is-psma-pet-ct-a-helpful-tool-in-radiation-oncology
#6
Laila König, Henrik Hauswald, Christa Flechtenmacher, Martina Heller, Jürgen Debus, Uwe Haberkorn, Clemens Kratochwil, Frederik Giesel
This case report shows the high PSMA-uptake in a patient with an adenoid cystic carcinoma of the maxillary sinus. Due to the intense ligand-uptake additional information for target volume delineation was obtained and the Treatment plan for bimodal radiotherapy with carbon ions was adapted accordingly.
December 2017: Clinical and Translational Radiation Oncology
https://www.readbyqxmd.com/read/29486883/photodynamic-therapy-and-diagnosis-principles-and-comparative-aspects
#7
REVIEW
Jane Dobson, Genilson Fernandes de Queiroz, Jon P Golding
Photodynamic therapy (PDT) is an evolving method of treating superficial tumours that is non-invasive and carries minimal risk of toxicity. It combines tumour-selective photosensitiser dyes, tissue oxygen and targeted illumination to generate cytotoxic reactive oxygen species (ROS) within the tumour. In addition to directly acting on tumour cells, PDT damages and restricts tumour microvasculature, and causes a local inflammatory response that stimulates an immune response against the tumour. Unlike surgery or radiotherapy, the surrounding extracellular matrix is unaffected by PDT; thus, tissue healing is excellent and PDT seldom causes scars...
March 2018: Veterinary Journal
https://www.readbyqxmd.com/read/29434991/mechanism-of-the-anti-angiogenic-effect-of-avemar-on-tumor-cells
#8
Nilüfer Gülmen Imir, Esra Aydemir, Ece Şimşek
Avemar, a derivative of fermented wheat germ extract, is a non-toxic and natural compound that is used as a dietary supplement by cancer patients undergoing chemotherapy and radiotherapy. Avemar has numerous biological activities, and several recent studies have reported that it may also have metastatic and anti-angiogenic effects. In the present study, the mechanism of the anti-angiogenic effect of Avemar on human cancer cells was investigated. The human cell lines NCI-N87 (gastric tubular adenocarcinoma), PC3 (prostate carcinoma), HeLa (endocervical adenocarcinoma) and A549 (lung adenocarcinoma) were treated with various doses (400, 800, 1,600 and 3,200 µg/ml) of Avemar, and the changes in mRNA and protein levels of two important markers of angiogenesis, vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (Cox-2), were assessed by reverse transcription-quantitative polymerase chain reaction and ELISA...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29190707/hypofractionated-stereotactic-boost-in-intermediate-risk-prostate-carcinoma-preliminary-results-of-a-multicenter-phase-ii-trial-ckno-pro
#9
David Pasquier, Philippe Nickers, Didier Peiffert, Philippe Maingon, Pascal Pommier, Thomas Lacornerie, Geoffrey Martinage, Emmanuelle Tresch, Eric Lartigau
PURPOSE: Dose escalation may improve curability in intermediate-risk prostate carcinoma. A multicenter national program was developed to assess toxicity and tumor response with hypofractionated stereotactic boost after conventional radiotherapy in intermediate-risk prostate cancer. METHODS AND MATERIAL: Between August 2010 and April 2013, 76 patients with intermediated-risk prostate carcinoma were included in the study. A first course delivered 46 Gy by IMRT (68...
2017: PloS One
https://www.readbyqxmd.com/read/29151366/the-150-most-important-questions-in-cancer-research-and-clinical-oncology-series-questions-76-85-edited-by-chinese-journal-of-cancer
#10
EDITORIAL
(no author information available yet)
Since the beginning of 2017, Chinese Journal of Cancer has published a series of important questions in cancer research and clinical oncology to promote cancer research and accelerate collaborations. In this article, 10 questions are presented as followed. Question 76. How to develop effective therapeutics for cancer cachexia? Question 77. How can we develop preclinical animal models to recapitulate clinical situations of cancer patients for more effective anti-cancer drug development? Question 78. How can we develop novel effective therapeutics for pancreatic cancer and hepatocellular carcinoma? Question 79...
November 20, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/29139310/pudendal-nerve-injury-impairs-anorectal-function-and-health-related-quality-of-life-measures-%C3%A2-2-years-after-3d-conformal-radiotherapy-for-prostate-cancer
#11
Eng Eric Yeoh, Rochelle Botten, Addolorata Di Matteo, Marcus Tippett, Jonathon Hutton, Robert Fraser, Phillip G Dinning, David Wattchow
PURPOSE: To compare GI symptoms, measures of generic and disease specific health related quality of life (HRQoL), anorectal and pudendal nerve function and anal sphincter morphology between (i) patients ≥2 years after 3D conformal radiotherapy (3D-CRT)±high dose rate (HDR) brachytherapy for carcinoma of the prostate and aged matched patients before radiotherapy and (ii) symptomatic and asymptomatic patients ≥2 years after 3D-CRT ± HDR brachytherapy. MATERIAL AND METHODS: Methodology included: (i) modified LENT-SOMA scales for GI symptoms, (ii) EORTC QLQ-C30 and EORTC QLQ-PR25 questionnaires for generic and disease specific HRQoL, (iii) anorectal manometry and terminal motor latency for anorectal and pudendal nerve function and (iv) endorectal ultrasound for anal sphincter morphology...
November 15, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29129577/pelvic-bone-anatomy-vs-implanted-gold-seed-marker-registration-for-image-guided-intensity-modulated-radiotherapy-for-prostate-carcinoma-comparative-analysis-of-inter-fraction-motion-and-toxicities
#12
Madhup Rastogi, Sambit Swarup Nanda, Ajeet Kumar Gandhi, Divakar Dalela, Rohini Khurana, Surendra Prasad Mishra, Anoop Srivastava, S Farzana, Madan Lal Brahma Bhatt, Nuzhat Husain
OBJECTIVES: We compared the prostate motion variability and toxicities between patients treated with gold marker registration based IG-IMRT (IG-IMRT-M) and bony landmark registration based IG-IMRT (IG-IMRT-B). METHODS: T1c-T3b (node negative), intermediate and high risk (non-metastatic) adenocarcinoma of prostate, age ≥18years, Karnofsky Performance Status of ≥70 were included in this retrospective study. The prostate motion variability, acute and late radiation toxicities between the two treatment arms (IG-IMRT-M versus IG-IMRT-B) were compared...
December 2017: Journal of the Egyptian National Cancer Institute
https://www.readbyqxmd.com/read/29121984/carbon-ion-radiotherapy-impact-of-tumor-differentiation-on-local-control-in-experimental-prostate-carcinomas
#13
Christin Glowa, Peter Peschke, Stephan Brons, Oliver C Neels, Klaus Kopka, Jürgen Debus, Christian P Karger
BACKGROUND: To summarize the research activities of the "clinical research group heavy ion therapy", funded by the German Research Foundation (DFG, KFO 214), on the impact of intrinsic tumor characteristics (grading, hypoxia) on local tumor control after carbon (12 C-) ion- and photon irradiations. METHODS: Three sublines of syngeneic rat prostate tumors (R3327) with various differentiation levels (highly (-H), moderately (-HI) or anaplastic (-AT1), (diameter 10 mm) were irradiated with 1, 2 and 6 fractions of either12 C-ions or 6 MV photons using increasing dose levels...
November 9, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/29066704/-two-cases-of-unresectable-advanced-rectal-cancer-with-a-long-term-survival-for-which-pathological-complete-response-was-achieved-through-neoadjuvant-effective-chemotherapy
#14
Kenji Gonda, Yosuke Tachiya, Yuichi Hatakeyama, Masahiko Shibata, Koji Kono, Yuichi Rokkaku
We report 2 unusual cases of Stage IV rectal cancer for which pathological complete response was achieved with neoadjuvant chemotherapy(NAC)consisting of a combination of 5-fluorouracil(5-FU), oxaliplatin, Leucovorin(mFOLFOX6)or irinotecan(FOLFIRI), and bevacizumab, without radiotherapy. Case 1: A 65-year-old man was diagnosed as having rectal cancer with an invasive carcinoma of the prostate and lymph node metastasis. He refused to undergo surgery and received NAC instead. After NAC with mFOLFOX6 and FOLFIRI was performed, CT scan and colonoscopy revealed no evidence of disease...
October 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28982907/hypofractionated-postoperative-imrt-in-prostate-carcinoma-a-phase-i-ii-study
#15
Gabriella Macchia, Giambattista Siepe, Ilaria Capocaccia, Nam P Nguyen, Riccardo Schiavina, Silvia Cammelli, Sara Guerri, Alessandra Arcelli, Milly Buwenge, Maria Ntreta, Savino Cilla, Vincenzo Valentini, Francesco Deodato, Alessio G Morganti
AIM: To report the outcome of hypofractionated radiotherapy after radical prostatectomy (RP) for prostate cancer (PCa) using simultaneous integrated boost-intensity modulated radiation therapy (SIB-IMRT). PATIENTS AND METHODS: A total of 124 patients with PCa at high risk of relapse after RP or diagnosis of biochemical relapse were included. Patients received 62.5 Gy to the prostate bed and 45 Gy to pelvic nodes in 25 fractions. Androgen-suppressive therapy was prescribed based on National Comprehensive Cancer Network risk categories...
October 2017: Anticancer Research
https://www.readbyqxmd.com/read/28971750/the-synergy-between-ionizing-radiation-and-immunotherapy-in-the-treatment-of-prostate-cancer
#16
Niranjan J Sathianathen, Suprita Krishna, Badrinath R Konety, Thomas S Griffith
There has been a surge in the use of immunotherapy for genitourinary malignancies. Immunotherapy is an established treatment for metastatic renal cell carcinoma and nonmuscle invasive bladder cancer, but its potential for treating prostate cancer (PCa) remains under investigation. Despite reported survival benefits, no published Phase III PCa trials using immunotherapy only as a treatment has demonstrated direct antitumor effects by reducing prostate-specific antigen levels. Subsequently, the thought of combining immunotherapy with other treatment modalities has gained traction as a way to achieving optimal results...
September 2017: Immunotherapy
https://www.readbyqxmd.com/read/28920149/efficacy-and-safety-of-153-sm-edtmp-as-treatment-of-painful-bone-metastasis-a-large-single-center-study
#17
Hélène Kolesnikov-Gauthier, Nathalie Lemoine, Emmanuelle Tresch-Bruneel, Anaïs Olivier, Aurore Oudoux, Nicolas Penel
PURPOSE: The purpose of this study is to assess the efficacy of 153 Sm-EDTMP (Quadramet®) in a clinical setting. METHODS: We have conducted a retrospective study of all consecutive patients (pts) treated with 153 Sm-EDTMP for painful bone metastases. At each visit (before and after treatment), four parameters were collected: (i) pain assessment according to the 10-step visual analogue scale (VAS), (ii) sleep disturbance related to pain, (iii) dose of analgesic medication, and (iv) answer to the following closed question "Do you think you obtained a benefit from treatment?" Success of treatment was defined by the combination of these four parameters...
March 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28919294/studying-the-efficacy-of-escalated-dose-conformal-radiation-therapy-in-prostate-carcinoma-pakistan-experience
#18
Asad Zamir, Ahmad Farooq, Hasan Nisar, Ismat Fatima, Irfan Ullah Khan, Misbah Masood, Abubaker Shahid
BACKGROUND: Our objective in this study was to evaluate the role and benefits in terms of local toxicity and biochemical disease-free survival (bDFS) following escalated-dose conformal radiation therapy in prostate adenocarcinoma. METHODS: The study population was composed of 53 patients with histologically proven T1b-T4, NO, MO prostate adenocarcinoma, having any Gleason score with prostate-specific antigen (PSA) of less than 50 ng/mL at diagnosis, given escalated dose EBRT (74 Gy) during the period between January 2011 and December 2013, retrospectively and evaluated for a period of 2 years post-radiation...
September 14, 2017: Journal of the Chinese Medical Association: JCMA
https://www.readbyqxmd.com/read/28833667/dual-nuclide-radiopharmaceuticals-for-positron-emission-tomography-based-dosimetry-in-radiotherapy
#19
Alexander Wurzer, Christof Seidl, Alfred Morgenstern, Frank Bruchertseifer, Markus Schwaiger, Hans-Jürgen Wester, Johannes Notni
Improvement of the accuracy of dosimetry in radionuclide therapy has the potential to increase patient safety and therapeutic outcomes. Although positron emission tomography (PET) is ideally suited for acquisition of dosimetric data because PET is inherently quantitative and offers high sensitivity and spatial resolution, it is not directly applicable for this purpose because common therapeutic radionuclides lack the necessary positron emission. This work reports on the synthesis of dual-nuclide labeled radiopharmaceuticals with therapeutic and PET functionality, which are based on common and widely available metal radionuclides...
January 12, 2018: Chemistry: a European Journal
https://www.readbyqxmd.com/read/28803033/the-risk-of-tumour-recurrence-in-patients-undergoing-renal-transplantation-for-end-stage-renal-disease-after-previous-treatment-for-a-urological-cancer-a-systematic-review
#20
REVIEW
Romain Boissier, Vital Hevia, Harman Max Bruins, Klemens Budde, Arnaldo Figueiredo, Enrique Lledó-García, Jonathon Olsburgh, Heinz Regele, Claire Fraser Taylor, Rhana Hassan Zakri, Cathy Yuhong Yuan, Alberto Breda
CONTEXT: Renal transplantation is the gold standard renal replacement therapy in end-stage renal disease owing to its superior survival and quality of life compared with dialysis. When the potential recipient has a history of cancer, the waiting period before renal transplantation is usually based on the Cincinnati Registry. OBJECTIVE: To systematically review all available evidence on the risk of cancer recurrence in end-stage renal disease patients with a history of urological cancer...
January 2018: European Urology
keyword
keyword
55063
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"